Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Intra-Articular Purified Exosome Product and Hyaluronan Attenuate Osteoarthritis Progression in a Minimally Invasive Turkey Model.

Journal of orthopaedic research : official publication of the Orthopaedic Research Society·2026

Same author

EUROVISCO Recommendations for the Use of Viscosupplementation with Hyaluronic Acid in the Management of Hip Osteoarthritis.

Cartilage·2026

Same author

Osteoarthritis Gene Therapy: A 30-Year Journey From Concept to Clinical Trials.

Journal of orthopaedic research : official publication of the Orthopaedic Research Society·2026

Same author

Lyophilization of Adeno-Associated Virus Serotypes for Storage and Global Distribution.

Biomedicines·2026

Same author

More arthritis gene therapy.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Same author

A new biochemical score from synovial fluid for diagnosing septic arthritis.

Joint bone spine·2025

Same journal

Preface.

Physical medicine and rehabilitation clinics of North America·2026

Same journal

Pain Unbound: A Comprehensive Review.

Physical medicine and rehabilitation clinics of North America·2026

Same journal

Dual Frontiers Cancer and Palliative Care.

Physical medicine and rehabilitation clinics of North America·2026

Same journal

Pain Management Across Special Populations: Pediatrics, Geriatrics, and Pregnancy.

Physical medicine and rehabilitation clinics of North America·2026

Same journal

Healing from Within: Regenerative Medicine in Pain Therapy.

Physical medicine and rehabilitation clinics of North America·2026

Same journal

The Brain in Pain: Exploring Central Pain Disorders.

Physical medicine and rehabilitation clinics of North America·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 13, 2026

Production of Modified Autologous Conditioned Serum and Ex Vivo Assessment of Its Healing Potential in Murine Corneal Epithelium

Production of Modified Autologous Conditioned Serum and Ex Vivo Assessment of Its Healing Potential in Murine Corneal Epithelium

Published on: March 24, 2023

Autologous Conditioned Serum.

Christopher H Evans¹, Xavier Chevalier², Peter Wehling³

¹Rehabilitation Medicine Research Center, Mayo Clinic, 200, First Street Southwest, Rochester, MN 55905, USA.

Physical Medicine and Rehabilitation Clinics of North America

|October 30, 2016

Summary

This summary is machine-generated.

Autologous conditioned serum (ACS) effectively generates interleukin-1 receptor antagonist to treat musculoskeletal inflammation and pain. This safe and practical therapy shows promise for various conditions like osteoarthritis and injuries.

Keywords:

Anterior cruciate ligament Interleukin-1 receptor antagonist Intra-articular therapy Muscle injury Osteoarthritis Pain Radicular compression Tendinopathy

More Related Videos

Mesenchymal Stromal Cell Culture and Delivery in Autologous Conditions: A Smart Approach for Orthopedic Applications

Mesenchymal Stromal Cell Culture and Delivery in Autologous Conditions: A Smart Approach for Orthopedic Applications

Published on: December 8, 2016

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Related Experiment Videos

Last Updated: Mar 13, 2026

Production of Modified Autologous Conditioned Serum and Ex Vivo Assessment of Its Healing Potential in Murine Corneal Epithelium

Production of Modified Autologous Conditioned Serum and Ex Vivo Assessment of Its Healing Potential in Murine Corneal Epithelium

Published on: March 24, 2023

Mesenchymal Stromal Cell Culture and Delivery in Autologous Conditions: A Smart Approach for Orthopedic Applications

Mesenchymal Stromal Cell Culture and Delivery in Autologous Conditions: A Smart Approach for Orthopedic Applications

Published on: December 8, 2016

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Area of Science:

Orthopedics
Regenerative Medicine
Biotechnology

Background:

Interleukin-1 (IL-1) is a key mediator in musculoskeletal inflammation, pain, and tissue damage.
Autologous conditioned serum (ACS) is a therapy developed to counteract IL-1 effects.
Musculoskeletal conditions like osteoarthritis and injuries involve significant inflammation and pain.

Purpose of the Study:

To introduce autologous conditioned serum (ACS) as a method for generating interleukin-1 receptor antagonist.
To review the applications and efficacy of ACS in treating musculoskeletal disorders.
To highlight the safety and practicality of ACS therapy.

Main Methods:

Development of ACS involves processing the patient's own blood to generate therapeutic factors.
Local administration of ACS for treatment of various musculoskeletal conditions.
Evaluation of ACS efficacy and safety based on clinical experience and outcomes.

Main Results:

ACS successfully generates interleukin-1 receptor antagonist, inhibiting IL-1 activity.
Widely successful use of ACS in treating human and equine osteoarthritis and radicular compression.
Promising results for ACS in tendinopathies, muscle injuries, and ACL reconstruction tunnel widening.

Conclusions:

Autologous conditioned serum (ACS) is a safe and effective treatment for various musculoskeletal conditions.
ACS offers a practical and relatively inexpensive approach to managing inflammation and pain.
The therapeutic potential of ACS extends to a range of orthopedic and sports-related injuries.